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Magnetic resonance imaging (MRI) is a non-invasive method that contributes to identify and 
characterize tumour tissues. The image contrast obtained in MRI depends essentially on the 
differences in the intensity of the water proton signals in different tissues. In order to increase the 
sensitivity of the technique, contrast agents (CA) containing paramagnetic metal ions such as Gd(III) 
are usually employed. For MRI applications, those paramagnetic species are strongly chelated by 
diethylenetriamine pentaacetic acid (DTPA) (scheme 1) or 1,4,7,10-Tetraazacyclododecane-1,4,7,10-
tetraacetic acid (DOTA) (scheme 2) in order to avoid the deposition of the highly toxic Gd(III) species 
on bones. Although those contrast agents are commonly used in MRI studies, they present some 
limitations such as a short lifetime in blood and a poor contrast when high magnetic fields (1.5T 
actually) are used for imaging.  
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The aim of our work is to improve the blood lifetime and the contrasting efficiency of the contrast 
agent, and to target it to tumor tissues in order to reduce the dose of contrast agent needed for 
satisfactory image acquisition. For that purpose, we will therefore report on the immobilization of 
gadolinium complexes onto biocompatible functional micelles in mild aqueous conditions with the 
formation of novel macrocontrast agents. The synthetic procedure will be first detailed. Then, the 
superiority of our macrocontrast agents in term of contrasting efficiency compared to commercially 
available gadolinium based contrast agents will be demonstrated by comparing the full relaxometric 
data over a broad magnetic field range (from 0.01 to 100 MHz). The hemolytic CH50 test will also 
demonstrate that our macrocontrast agent is not recognize by the immune system, which should 
consequently avoid their fast elimination from the body. The improved relaxivity and the stealthiness 
of the macrocontrast agent make it an excellent candidate for MRI blood pool agent.  
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